Diabetes

Semaglutide prescribed in clinical practice helped more than half of study participants achieve weight loss of ≥10% at 6 months.

Tirzepatide in an exploratory analysis of SURPASS-2 and -3 trials added proof of shorter time to glycemic targets and weight loss goals to superior reduction of HbA1c.

Nocturnal HTN is a risk factor for cardiovascular disease and stroke. How do you diagnose and treat in your practice? Test your overnight BP IQ.

Data from the pivotal phase 3 FIGARO-DKD cardiovascular outcomes trial with finerenone reaffirms the agent's dual cardiorenal risk reduction benefits in T2D-associated CKD.

A 5-fold greater risk for all-cause or CVD-related death in persons diagnosed with T2D before age 40 years should be a call to action for enhanced screening, study authors state.

Blood pressure-lowering therapy reduced the risk of major CV events in persons with and without type 2 diabetes, according to an individual participant-level data meta-analysis.

Youth newly diagnosed with T2D also were metabolically sicker, with higher HbA1c, serum glucose levels, and BMI at presentation.

Phase II clinical trial shows a fixed dose combination of semaglutide/cagrilintide reduces HbA1c and weight much better than either drug alone.

The woman is in her mid-fifties, diarrhea has been persistent for 10 days and BUQ pain for 2 days. What does the CT show? What's your diagnosis?

Analysis of 224 000 type 2 diabetes patients over 2 decades suggests the need for "revised care pathways" that better reflect the myriad causes of persistent morbidity.

The USPSTF guidance supports shared decision making with patients without CVD risk factors who may benefit from behavioral counseling on diet and physical activity.

Food consumption confined to a 10-hour period for adults with T2D led to increased time in range and lowered nocturnal and fasting glucose.

The GLP-1 RA given once weekly to T2D patients with hyperglycemia not controlled by diet and exercise lowered HbA1c to ≤6.5% in approximately half the study population.

Type 1 diabetes diagnoses increased by 81% during the 4-week acute phase of COVID-19 in UK patients and CVD diagnoses rose 6-fold, according to a large population-based study.

These 11 studies of cardiovascular and metabolic disease prevention, assessment, and treatment were top trending topics on Patient Care in the first half of 2022.

Medicare Advantage plans may cut treatment corners to avoid more costly but more effective and targeted therapy for diabetes patients.

From type 2 diabetes to chronic yeast infection, we have picked the top 7 FDA-approved drugs every primary care physician should know about from the second quarter.

Less than 7% of the US population has "optimal" cardiometabolic health, with declines over 20 years significantly affecting racial/ethnic populations.

US CV health is well below ideal, with 80% of adults scoring as only low or moderate in the first published study using AHA's new Life's Essential 8 algorithm.

Slide Show: The AHA added sleep duration to its Life's Simple 7 cardiovascular health construct and updated sections on diet, lipids, blood glucose and smoking.

Non-Hispanic Black and Hispanic adults with undiagnosed prediabetes are less likely than White adults to appreciate their risk for overt type 2 diabetes.

The cost of continuous glucose monitors must be covered for persons with type 1 and type 2 diabetes in the state of Illinois based on a bill signed into law this month.

ENDO 2022. Age, body mass index, gender, race, and certain comorbidities may influence a diagnosis of prediabetes in primary care settings, suggests new study.

Empagliflozin was associated with a nearly 40% reduced risk of incident renal stone disease vs placebo in a large analysis of data pooled from randomized clinical trials.

A new study found patients with T1D and T2D had a greater risk for stenotic lesions, whereas risk for valvular regurgitation was lower in those with T2D.

ENDO 2022: The large US analysis found persons with prediabetes had increased odds for heart attack of 25%, for PCI of 45%, and had nearly double the risk of having CABG.

ADA 2022: Use of flash continuous glucose monitoring in T2D patients not on insulin also reduced HbA1c and glycemic variability, a new study finds.

ADA 2022: Large national study found that CGM use had a positive effect on glycemic control and acute complications in T2D in the Veterans Health Administration.

ADA 2022. Tirzepatide was associated with significantly greater TIR, many fewer episodes of hypoglycemia, and less glycemic excursion vs insulin degludec in SURPASS-3 CGM.